A Systematic Evaluation of the QTc Interval and Antidepressants in Youth: An Electronic Health Record Study

Journal of Developmental and Behavioral Pediatrics

Volumn 36, Issue 6, 2015, Pages 434-439

  Uchida, Mai ^a   Spencer, Andrea E ^a   Biederman, Joseph ^a   Castro, Victor M ^b   Kenworthy, Tara ^a   Chan, James ^a   Rosales, Ana M ^a   Newton Cheh, Christopher ^a   Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

Author keywords

arrhythmia; electrocardiogram; medical record; pediatric; selective serotonin reuptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; METHADONE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; CHEMICALLY INDUCED; CHILD; ELECTROCARDIOGRAPHY; ELECTRONIC HEALTH RECORD; FEMALE; HUMAN; LONG QT SYNDROME; MALE; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METHADONE;

EID: 84937550312     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0000000000000188     Document Type: Article

References (16)

1. FDA. FDA drug safety communication: abnormal heart rhythms associated with high doses of celexa (citalopram hydrobromide). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm269086. htm#sa. Accessed January 2, 2014.
2. FDA. FDA drug safety communication: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: http://www. fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed January 2, 2014.
3. Wilens TE, Biederman J, March JS, et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38:573-577.
4. Krulewicz S, Carpenter DJ, Fong R, et al. Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:422-430.
5. Klein-Schwartz W, Benson BE, Lee SC, et al. Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children. Clin Toxicol (Phila). 2012;50:418-423.
6. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006;148:158-165.
7. Treatment for adolescents with depression study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2003; 42:531-542.
8. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62:165-172.
9. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
10. Tyl B, Azzam S, Blanco N, et al. Improvement and limitation of the reliability of automated qt measurement by recent algorithms. J Electrocardiol. 2011;44:320-325.
11. Keane JF, Fyler DC, Lock JE. Nadas' Pediatric Cardiology. 2nd ed. Philadelphia, PA: Saunders; 2006.
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
13. Lenth RV. Lsmeans: Least-Squares Means. R Package Version 1.10-4. Available at: http://CRAN.R-Project.org/package5lsmeans. Accessed March 26, 2014.
14. Schwartz PJ, Crotti L. Ion channel diseases in children: manifestations and management. Curr Opin Cardiol. 2008;23:184-191.
15. Montanez A, Ruskin JN, Hebert PR, et al. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004;164:943-948.
16. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;163:1898-1904.